Jason Gerberry
Stock Analyst at B of A Securities
(3.72)
# 759
Out of 5,008 analysts
162
Total ratings
57.76%
Success rate
5.11%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $81 → $83 | $68.94 | +20.39% | 6 | Sep 23, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $25.83 | +23.89% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $16.11 | +86.22% | 6 | Aug 12, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $49 | $15.02 | +226.23% | 2 | Aug 12, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $173 → $176 | $118.64 | +48.35% | 6 | Aug 5, 2025 | |
| PROK ProKidney | Downgrades: Underperform | $3 → $1 | $2.96 | -66.22% | 4 | Jun 30, 2025 | |
| LQDA Liquidia | Maintains: Buy | $25 → $23 | $24.03 | -4.27% | 2 | Jun 11, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $45 → $46 | $39.63 | +16.07% | 3 | Jun 5, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $20 → $22 | $20.07 | +9.62% | 14 | May 8, 2025 | |
| PCVX Vaxcyte | Maintains: Buy | $157 → $137 | $41.87 | +227.20% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $10.14 | -1.38% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $20.82 | +44.09% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $85.21 | +17.36% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $5.83 | +311.66% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $19.06 | +4.93% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $34.93 | -11.25% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $7.59 | +7,146.38% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $30.95 | -6.30% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $36.54 | +1.26% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $39.16 | +43.00% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $27.05 | +10.91% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $137.32 | +58.03% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $100 → $50 | $11.07 | +351.67% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $843.63 | -40.73% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.35 | +566.67% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $10.60 | +135.85% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.80 | +178.55% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $6.39 | +322.54% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.71 | +1,069.59% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $4.61 | +2,069.20% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $232.83 | -59.20% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $44.66 | +34.35% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $26.27 | +40.85% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $87.61 | +2.73% | 11 | Oct 17, 2019 |
Ionis Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $81 → $83
Current: $68.94
Upside: +20.39%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $25.83
Upside: +23.89%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $16.11
Upside: +86.22%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $15.02
Upside: +226.23%
Axsome Therapeutics
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $118.64
Upside: +48.35%
ProKidney
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.96
Upside: -66.22%
Liquidia
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $24.03
Upside: -4.27%
Exelixis
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $39.63
Upside: +16.07%
Teva Pharmaceutical Industries
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $20.07
Upside: +9.62%
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $41.87
Upside: +227.20%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $10.14
Upside: -1.38%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $20.82
Upside: +44.09%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $85.21
Upside: +17.36%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $5.83
Upside: +311.66%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $19.06
Upside: +4.93%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $34.93
Upside: -11.25%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $7.59
Upside: +7,146.38%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $30.95
Upside: -6.30%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $36.54
Upside: +1.26%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $39.16
Upside: +43.00%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $27.05
Upside: +10.91%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $137.32
Upside: +58.03%
Aug 8, 2023
Downgrades: Underperform
Price Target: $100 → $50
Current: $11.07
Upside: +351.67%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $843.63
Upside: -40.73%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.35
Upside: +566.67%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $10.60
Upside: +135.85%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.80
Upside: +178.55%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $6.39
Upside: +322.54%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.71
Upside: +1,069.59%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $4.61
Upside: +2,069.20%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $232.83
Upside: -59.20%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $44.66
Upside: +34.35%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $26.27
Upside: +40.85%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $87.61
Upside: +2.73%